Research
Hormonal
Metformin is the preferred initial oral hypoglycemic agent for Type 2 Diabetes Mellitus due to its excellent blood glucose-lowering effect, relatively low side effects, long-term safety, low risk of hypoglycemia, and low weight gain.
Start metformin at a low dose and increase it slowly to minimize stomach upset. It is the standard first-line treatment because it lowers blood sugar effectively without causing significant weight gain or hypoglycemia.
GoodSupportsHIGH confidence
Metformin is recommended as the first choice for patients with T2DM because of its excellent blood glucose-lowering effect, relatively low adverse effects, long-term safety, low risk of hypoglycemia, and low weight gain.
Why this rating
Based on a systematic review of multiple guidelines and cohort studies, though some CV outcomes are not fully ascertained.
Source
Monotherapy in Patients with Type 2 Diabetes Mellitus
Sang Youl Rhee et al. · Diabetes & Metabolism Journal · 2017
DOI 10.4093/dmj.2017.41.5.349
clinical_guidelineCited 19×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT2 inhibitors reduce cardiovascular disease risk and mortality in Type 2 Diabetes patients, but are associated with increased risks of urogenital infections, dehydration, hypotension, osteoporotic fractures, and limb amputation.Good
- DPP4 inhibitors are effective substitutes for metformin with low hypoglycemia risk, but their cardiovascular effects are neutral and they may slightly increase heart failure risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →